Liposomal Bupivacaine for Pain Control Following Thoracic Surgery.
Pain, Postoperative, Thoracic Diseases, Local Anesthetics Causing Adverse Effects in Therapeutic Use
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring postoperative pain, video-assisted thoracoscopic surgery (VATS), opioids, bupivacaine, liposomal bupivacaine, analgesia, local anesthetics
Eligibility Criteria
Inclusion Criteria:
- Eligible patients would be all patients aged older than 18 years who undergo a video-assisted thoracoscopic lung resection at Massachusetts General Hospital.
Exclusion Criteria:
- Pregnant women, prisoners, emergent cases, patients under 18 years, and patients with chronic pain, documented alcohol or drug abuse and allergies to bupivacaine will be excluded from this study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Bupivacaine
Liposomal bupivacaine
Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.